Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 1/20 | 0.68 |
| ▸ | PTAFR | P25105 | 1/20 | 0.68 |
| ▸ | HTR1D | P28221 | 1/20 | 0.68 |
| ▸ | HTR2C | P28335 | 1/20 | 0.68 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.68 |
| ▸ | DRD3 | P35462 | 1/20 | 0.68 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.53 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | GMNN | O75496 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | BLM | P54132 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.51 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.51 |
| ▸ | PRKCG | P05129 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29977369 | 1.00 | ADRA1D (0.68) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL19821628 | 0.88 | MAPT (0.71) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL30278565 | 0.88 | MAPT (0.71) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL3405063 | 0.86 | SMN1; SMN2 (0.60) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL15263707 | 0.85 | ADRA1D (0.78) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL3409969 | 0.84 | SMN1; SMN2 (0.67) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL30649908 | 0.84 | SMN1; SMN2 (0.67) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL17761142 | 0.84 | SMN1; SMN2 (0.68) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL6904233 | 0.84 | SMN1; SMN2 (0.68) | ADRA1DPTAFRHTR1DHTR2CADRA1B | |
| SCHEMBL29458110 | 0.84 | SMN1; SMN2 (0.68) | ADRA1DPTAFRHTR1DHTR2CADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220387-A2 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| EP-1626728-A4 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | VASCULAR BIOGENICS LTD (IL) | 2009-09-02 | — | — | EP | disclosed |
| EP-1924527-A1 | FILM COMPRISING SILICATE PLATELETS EXFOLIATED FROM PHOSPHOLIPID-INTERCALATED LAYERED SILICATE | Cryovac, Inc. (US) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007024576-A1 | FILM COMPRISING SILICATE PLATELETS EXFOLIATED FROM PHOSPHOLIPID-INTERCALATED LAYERED SILICATE | CRYOVAC, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| EP-1626728-A2 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | Vascular Biogenics Ltd. (IL) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004106486-A2 | OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS | VASCULAR BIOGENICS LTD. (IL) | 2004-12-09 | — | — | WO | disclosed |
| US-20040047903-A1 | D and L etherlipid stereoisomers and liposomes | ELAN PHARMACEUTICALS, INC. | 2004-03-11 | — | — | US | disclosed |
| US-6667053-B1 | Liposome having lipid bilayer comprising optically active ether lipid anti-cancer agent component, underivatized phosphatidylcholine, sterol, and phosphatidylethanolamine linked to dicarboxylic acid at ethanolamine group | ELAN PHARMACEUTICALS, INC. | 2003-12-23 | — | — | US | disclosed |
| US-6573246-B1 | Anticancer agents | THE LIPOSOME COMPANY, INC. | 2003-06-03 | — | — | US | disclosed |
| EP-1267835-A1 | D AND L ETHERLIPID STEREOISOMERS AND LIPOSOMES | The Liposome Company, Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001074333-A1 | D AND L ETHERLIPID STEREOISOMERS AND LIPOSOMES | THE LIPOSOME COMPANY, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
| US-6153736-A | ANTICANCER AGENTS | THE LIPOSOME COMPANY, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| EP-0161519-B1 | DERIVATIVES OF GLYCEROPHOSPHOCHOLINE AND OF GLYCEROPHOSPHOETHANOL AMINE, THEIR PREPARATION AND USE | CHEMIE LINZ AKTIENGESELLSCHAFT (AT) | 1988-06-29 | — | — | EP | disclosed |
| US-4717512-A | Preparation of acylated glycerophosphocholines and glycerophosphoethanolamines | CHEMIE LINZ AKTIENGESELLSCHAFT (AT) | 1988-01-05 | — | — | US | disclosed |
| US-4622180-A | Derivatives of glycerophosphocholine and glycerophosphoethanolamine, their preparation and their use | CHEMIE LINZ AKTIENGESELLSCHAFT (AT) | 1986-11-11 | — | — | US | disclosed |
| EP-0161519-A2 | Derivatives of glycerophosphocholine and of glycerophosphoethanol amine, their preparation and use | CHEMIE LINZ AKTIENGESELLSCHAFT (AT) | 1985-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | ADRA1D 1631/4885PTAFR 684/4885HTR1D 3764/4885 |
| US-20040047903-A1 | D and L etherlipid stereoisomers and liposomes | DEGS1, DLD, PLD2 | ADRA1D 428/4885PTAFR 3198/4885HTR1D 2179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.